BPG is committed to discovery and dissemination of knowledge
Homepage
Online Submission
Number of total visits
3161112
Number of visits today
2352
Number of downloads
2314641
MEMBERSHIP
Cited by in F6Publishing
Number
Citing Articles
1
Garred P , Tenner AJ , Mollnes TE . Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73 :792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072 ] [ Cited by in Crossref: 6] [ Cited by in F6Publishing: 8 ] [ Article Influence: 6.0 ] [ Reference Citation Analysis ]
2
Caetano R , Cordeiro Dias Villela Correa M , Villardi P , Almeida Rodrigues PH , Garcia Serpa Osorio-de-Castro C . Dynamics of patents, orphan drug designation, licensing, and revenues from drugs for rare diseases: The market expansion of eculizumab. PLoS One 2021;16 :e0247853. [PMID: 33667235 DOI: 10.1371/journal.pone.0247853 ] [ Reference Citation Analysis ]
3
Lee SE , Lee JW . Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf 2021;20 :171-9. [PMID: 33249943 DOI: 10.1080/14740338.2021.1857723 ] [ Cited by in F6Publishing: 2 ] [ Reference Citation Analysis ]
4
Doll H , Coşkun U , Hartford C , Tomazos I . Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria. J Patient Rep Outcomes 2021;5 :45. [PMID: 34152498 DOI: 10.1186/s41687-021-00319-9 ] [ Reference Citation Analysis ]
5
Barratt J , Weitz I . Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Front Immunol 2021;12 :712572. [PMID: 34566967 DOI: 10.3389/fimmu.2021.712572 ] [ Reference Citation Analysis ]
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA California Corporate Number: 3537345
